Phone: 888-558-5227

651-644-8424

888-558-7329 Fax: Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID C3260 CAS No. 52214-84-3

Chemical Name

Synonym

Formula C₁₃H₁₄Cl₂O₃ Formula Wt. 289.16 Melting Point 114-120°C Purity ≥98%

Solubility Practically insoluble in

water, freely soluble in anhydrous ethanol, soluble

in toluene

Store Temp 4°C Ship Temp Ambient

Description Ciprofibrate is a PPARα agonist that exhibits anti-hyperlipidemic activity. Clinically, ciprofibrate decreases levels of

triglycerides and total cholesterol and increases levels of HDL. In hepatoma cells, ciprofibrate increases NF-κB DNA binding activity. Additionally, ciprofibrate induces depolarization of the mitochondrial membrane potential, which may be involved in

its mechanism of enhancing peroxisome proliferation.

Bulk quanitites available upon request

Product ID Size C3260 25 mg C3260 100 mg

References Aguilar-Salinas CA, Assis-Luores-Vale A, Stockins B, et al. Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study). Cardiovasc Diabetol. 2004 Jul 23;3:8. PMID: 15272932.

> Li Y, Glauert HP, Spear BT. Activation of nuclear factor-kappaB by the peroxisome proliferator ciprofibrate in H4IIEC3 rat hepatoma cells and its inhibition by the antioxidants N-acetylcysteine and vitamin E. Biochem Pharmacol. 2000 Feb 15;59 (4):427-34. PMID: 10644051.

Zhou S, Wallace KB. The effect of peroxisome proliferators on mitochondrial bioenergetics. Toxicol Sci. 1999 Mar;48(1):82-9. PMID: 10330687.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.